# A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC

> **NCT04416035** · PHASE3 · UNKNOWN · sponsor: **Zhejiang Teruisi Pharmaceutical Inc.** · enrollment: 608 (estimated)

## Conditions studied

- Advanced Non-squamous Non-small-cell Lung Cancer

## Interventions

- **BIOLOGICAL:** TRS003
- **BIOLOGICAL:** China-approved Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04416035
- **Lead sponsor:** Zhejiang Teruisi Pharmaceutical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-17
- **Primary completion:** 2021-10-21
- **Final completion:** 2021-11-10
- **Target enrollment:** 608 (ESTIMATED)
- **Last updated:** 2020-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04416035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04416035, "A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04416035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*